Moderna Inc [NASDAQ: MRNA] price plunged by -1.37 percent to reach at -$0.37.
The one-year MRNA stock forecast points to a potential upside of 39.5. The average equity rating for MRNA stock is currently 2.86, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $43.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 13, 2025. While these analysts kept the previous recommendation, Barclays raised their target price from $111 to $45. The new note on the price target was released on February 18, 2025, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $99 to $51, while Goldman kept a Neutral rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc is set at 1.69, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 3.23. The Price to Book ratio for the last quarter was 1.02, with the Price to Cash per share for the same quarter was set at 15.45.
MRNA Stock Performance Analysis:
Moderna Inc [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.60. With this latest performance, MRNA shares dropped by -6.94% in over the last four-week period, additionally sinking by -39.17% over the last 6 months – not to mention a drop of -82.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 50.60, with the RSI for the last a single of trading hit 52.48, and the three-weeks RSI is set at 48.75 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 27.02, while it was recorded at 26.51 for the last single week of trading, and 44.20 for the last 200 days.
Insight into Moderna Inc Fundamentals:
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.14 and a Current Ratio set at 4.22.
MRNA Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc go to 20.91%.
Moderna Inc [MRNA] Institutonal Ownership Details
The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3149%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6569%.
